Rezolute, Inc. Common Stock (NV) (RZLT) is a publicly traded Healthcare sector company. As of May 21, 2026, RZLT trades at $3.23 with a market cap of $311.99M and a P/E ratio of -3.27. RZLT moved +3.87% today. Year to date, RZLT is +63.87%; over the trailing twelve months it is -18.48%. Its 52-week range spans $1.07 to $11.46. Analyst consensus is buy with an average price target of $6.25. Rallies surfaces RZLT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rezolute Logs $16.2M Q3 Loss with $120.3M Cash, Phase 3 Study Shows >50% Hypoglycemia Reduction: Rezolute ended Q3 FY2026 with $120.3M in cash, R&D expenses down to $11.4M and net loss improved to $16.2M from $18.9M a year ago. Expanded Phase 3 sunRIZE analyses showed >50% reductions in hypoglycemic time and events, while Phase 3 tumor HI enrollment proceeds with topline H2 2026.
| Metric | Value |
|---|---|
| Price | $3.23 |
| Market Cap | $311.99M |
| P/E Ratio | -3.27 |
| EPS | $-0.98 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.46 |
| 52-Week Low | $1.07 |
| Volume | 1.51K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-74.41M |
| Gross Margin | 0.00% |
6 analysts cover RZLT: 0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.25.